Diasorin is a specialist in molecular diagnostics and immunodiagnostics, providing technologies to detect physiological markers and diseases in human samples. Self-described as active in the Licensed Technology sector.

Diasorin

IBD Biomed develops biomedical devices for dialysis and non-invasive lung ventilation, focusing on making them economically accessible.

IBD Biomed

Overmed is an Italian medical device company that provides medical equipment and solutions.

OVERMED

Olympus Italia develops customer-oriented solutions for the medical sector. The company has been committed to making people's lives healthier, safer, and more rewarding for over 100 years. Self-described as focused on advancing medical technology.

Olympus Italia

Diasorin | 71,350 followers on LinkedIn. Diasorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics. Starting from 2021, the company also commercializes Life Science products. The Group was founded in 1968 and is headquartered in Saluggia (Italy).

Corporate VP @ Diasorin | Corporate Communications, ESG & Investor Relations

Riccardo Fava

Innovator in Global Talent Acquisition: Pioneering the Future of the Biotech Workforce 🌌

Jesse Nergard

Michael Howachyn

Global Sales & Commercial Operations Executive

Rodrigo Pellicciari

From November 18 to 24, 2024, Diasorin is participating in World Antimicrobial Resistance (AMR) Awareness Week. Our goal is to raise awareness about the global threat of antimicrobial resistance and to promote best practices that help curb the rise and spread of drug-resistant infections. By working together, we can support safer, more effective healthcare for all. #Diasorin #WorldAntimicrobialAwarenessWeek #AntimicrobialResistance #AMR

Healthcare-associated infections (HAIs) are a major threat to vulnerable hospital patients, affecting more than 1 million patients and resulting in thousands of deaths annually in the US. PCR-based molecular testing of patients suspected of HAIs is key to expediting pathogen detection and patient isolation to prevent potentially deadly HAI outbreaks. Learn more about HAIs in the latest ID Transmission by Dr. Ayaz Majid (Director, Product Mangement - Diasorin): https://hubs.li/Q02YfdQG0 Explore Diasorin’s molecular HAI testing menu: https://hubs.li/Q02YfrKM0 #HAI #Cauris #moleculartesting

Evaluating diabetic status is essential for accurate diagnosis and effective management of diabetes—a condition that impacts millions worldwide. At Diasorin, we are dedicated to advancing the prevention, diagnosis, and management of diabetes. Our mission is to empower patients, families, and healthcare providers with the tools and insights they need to tackle diabetes head-on and enhance quality of life. Together, we’re making strides toward a healthier future. #Diasorin #WorldDiabetesDay

We are continuing to build on our legacy blood culture portfolio with the submission of the LIAISON PLEX® Gram-Positive Blood Culture Assay on the sample-to-answer LIAISON PLEX® System. Gram-positive bacteremia accounts for approximately 60% of all positive blood cultures. Optimized treatment is crucial for saving patients’ lives, and assays built with our proprietary NanoGrid technology have been at the forefront of helping clinicians make critical therapeutic decisions in hours, not days.

Today is World Pneumonia Day, a reminder of the significant impact pneumonia has on global health, with high morbidity, mortality, and associated healthcare costs. To combat this serious infectious disease, Diasorin has been providing specific diagnostic tests for many years. This year, we are proud to introduce the LIAISON® Urinary Ag test, a new automated solution that delivers accurate and rapid results, enhancing our efforts in pneumonia diagnosis and in patient management. #Diasorin #WorldPneumoniaDay

When it comes to treating cCMV, early diagnosis is key. Unfortunately, 91% of women are unaware of the risk of CMV—a common herpes virus that is harmless in most healthy adults. When transmitted during pregnancy, CMV may cause hearing loss and long-term developmental issues in newborns. Early diagnosis is key for #healthymothersandbabies . The Simplexa® Congenital CMV Direct assay is the only FDA-cleared test that detects cCMV in both saliva swabs and confirmatory urine samples in newborns, under 21 days of age, to facilitate the accurate detection and diagnosis of cCMV. For better health in moms and babies, visit our extensive menu of best-in-class diagnostic tests to support women and neonatal health on our website: https://hubs.li/Q02XcB5l0 #cCMV #newbornhealth

Stay updated on what may or may not be covered regarding COVID-19 testing now that the pandemic is over, and COVID-19 is no longer a public health emergency. Whether your patients are covered under Medicare, Medicaid, or private insurance, or just want to know what safety nets are available for those uninsured, check out our blog summarizing what changes to coverage and reimbursement policies you might expect. Check out our blog: https://hubs.li/Q02Tqz7S0 #HealthcareReimbursement #Diasorin

It’s no secret that clinical labs are facing a perfect storm of challenges: rising costs, staff shortages, and increased demand. Check out our blog summarizing an interview with two Diasorin team members in Medical Laboratory Observer . Learn what solutions they shared regarding what Diasorin offers for optimizing respiratory testing through the customization of syndromic testing. Read the blog: https://hubs.li/Q02W_Tg70 #Diasorin #LIAISONPLEX

How can pneumonia diagnosis be improved, and what are the main challenges in consistently administering early targeted therapy? These topics will be explored during the webinar “Automated Urinary Antigen Testing in Pneumonia Patient Care” where we will provide background information on the main challenges when diagnosing pneumonia and introduce our new diagnostic approach to better pneumonia diagnosis. Only 3 days left until the webinar. Don’t miss it! Save the date and register: 🔗 https://lnkd.in/dC9w_JSq

The LIAISON® XL is designed with you in mind. By automating routine tasks and minimizing human error, it frees up your team to focus on what matters most: patient care. With a wider range of premium specialty tests, you can confidently address the growing challenges of infectious diseases, gastrointestinal health, and women's health. Our goal is to empower you to do more with less. Less manual work, less chance of errors, and less stress. More efficient workflows, more accurate results, and more satisfied patients. Are you ready to experience the LIAISON® XL difference? Visit today our page dedicated and contact us to learn more: https://lnkd.in/d9et5sfZ #LIAISONXL #laboratoryefficiency #patientcare #healthcareimprovement #clinicaldiagnostics

Metric
Company Name	Diasorin	IBD Biomed	OVERMED	Olympus Italia
Symbol
MSH ID	COM:DIASORIN:INT	COM:IBDBIOMED	EU:OVERMED	IT:OLYMPUS
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical Diagnostics	Medical Devices	Medical Devices	Medical Devices
Country	IT	IT	IT	IT
Stage				Post-IPO Equity
Employee Count
Website	int.diasorin.com	ibdbiomed.com	overmed.eu	olympus.it
LinkedIn	diasorin	ibd-biomed		olympus-italy
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	46	132.60K
Web Traffic Growth	4.50	-0.15
Valuation
Raised Capital		600M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

DIAS

COM:DIASORIN:INT

Diasorin

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue